Holen Sie sich die Stockscreener-App
6.22
2.05%
0.11
Schlusskurs vom Vortag:
$6.11
Offen:
$6.16
24-Stunden-Volumen:
1.88M
Relative Volume:
0.49
Marktkapitalisierung:
$1.54B
Einnahmen:
$427.68M
Nettoeinkommen (Verlust:
$-58.06M
KGV:
-26.11
EPS:
-0.2382
Netto-Cashflow:
$-37.50M
1W Leistung:
+2.38%
1M Leistung:
+4.79%
6M Leistung:
+5.14%
1J Leistung:
+57.05%
1-Tages-Spanne:
$6.08
$6.295
1-Wochen-Bereich:
$6.06
$6.44
52-Wochen-Spanne:
$3.49
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.225 | 1.51B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
436.71 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.15 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
This Insider Has Just Sold Shares In Ardelyx - simplywall.st
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
Ardelyx chief patient officer sells $43,803 in shares By Investing.com - Investing.com Canada
Ardelyx chief patient officer sells $43,803 in shares - Investing.com
Tax-related Ardelyx (ARDX) insider sale covers RSU withholding needs - Stock Titan
Ardelyx (ARDX) CFO executes 1,455-share tax sell-to-cover after RSU vest - Stock Titan
Ardelyx (ARDX) officer’s RSU vesting triggers 2,306-share tax sell - Stock Titan
Ardelyx (ARDX) HR chief sells 1,846 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) Chief Commercial Officer sells 7,998 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) chief business officer logs 7,248-share tax sell-to-cover - Stock Titan
Ardelyx (ARDX) Chief Patient Officer sells 6,989 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) CEO Raab executes 54,748-share RSU tax sell-to-cover - Stock Titan
Ardelyx president & CEO Michael Raab sells $261,612 of ARDX stock - Investing.com India
What Triggered Ardelyx's Post-Earnings Plunge - Kavout
Ardelyx Earnings Call Highlights Rapid Growth, Rising Costs - TipRanks
ARDX (NASDAQ: ARDX) files Form 144 for 24,986 RSUs vesting - Stock Titan
ARDX (NASDAQ: ARDX) reports 5,355 RSUs vest; insider sales noted - Stock Titan
James Parker Brady files Form 144 for 6,216 ARDX shares (ARDX) - Stock Titan
Proposed Common Stock Sale by ARDX Affiliate (NASDAQ: ARDX) - Stock Titan
ARDX (NASDAQ) insider reports 10,388 RSUs vesting; prior sales 4,991 shares - Stock Titan
Michael Raab reports multiple ARDX share sales (ARDX) and RSU vesting - Stock Titan
ARDX (NASDAQ: ARDX) files Form 144 for 7,771 vested RSUs and lists recent insider sales - Stock Titan
Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing - Moomoo
Insider sale reported for ARDX (ARDX): 24,041 RSU shares vest - Stock Titan
Ardelyx (ARDX) CEO sells 41,666 shares in 10b5-1 trade, exercises options - Stock Titan
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 - The Manila Times
A Look At Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Data Strengthens Safety And Efficacy Profile - simplywall.st
Ardelyx, Inc.Common Stock (NQ: ARDX - The Chronicle-Journal
Ardelyx (ARDX) Is Down 8.1% After New Long-Term XPHOZAH Dialysis DataHas The Bull Case Changed? - simplywall.st
Janus Henderson (ARDX) discloses 8.37M‑share, 3.4% position in Ardelyx - Stock Titan
ARDX Stock Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
ETFs Investing in Ardelyx, Inc. Stocks - TradingView
Ardelyx, Inc. $ARDX Stock Position Increased by Vanguard Group Inc. - MarketBeat
State Street (ARDX) reports 13.6M-share | 5.5% stake via advisory entities - Stock Titan
TradingKey - TradingKey
Assessing Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Safety Data Presentation - simplywall.st
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis PatientsWhat's Changed - Yahoo Finance
Why Ardelyx (ARDX) Is Up 10.3% After New Long-Term XPHOZAH Dialysis Data And What's Next - simplywall.st
Ardelyx: Low Price, But High Implied Valuation (NASDAQ:ARDX) - Seeking Alpha
Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing The 134% Potential Upside - DirectorsTalk Interviews
Ardelyx presents long-term safety data for XPHOZAH at NKF meeting By Investing.com - Investing.com South Africa
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance - Yahoo Finance
Ardelyx presents long-term safety data for XPHOZAH at NKF meeting - Investing.com
Dialysis drug cut phosphate without shifting other electrolytes in trials - Stock Titan
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - TMX Newsfile
Ardelyx (ARDX) Q1 2026 Earnings Transcript - AOL.com
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
Ardelyx (NASDAQ:ARDX) Strengthens Amid Biotech Momentum - Kalkine Media
Ardelyx, Inc. (NASDAQ:ARDX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Moomoo
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end - MSN
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ardelyx Inc-Aktie (ARDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hohenleitner Susan | Chief Financial Officer |
May 21 '26 |
Sale |
6.27 |
1,455 |
9,119 |
229,078 |
| Bishop John E | See Remarks |
May 21 '26 |
Sale |
6.27 |
2,306 |
14,453 |
336,845 |
| Brady James Parker | Chief Human Resources Officer |
May 21 '26 |
Sale |
6.27 |
1,846 |
11,570 |
261,066 |
| Foster Eric Duane | Chief Commercial Officer |
May 21 '26 |
Sale |
6.27 |
7,998 |
50,127 |
417,972 |
| Kelliher Mike | Chief Business Officer |
May 21 '26 |
Sale |
6.27 |
7,248 |
45,427 |
357,418 |
| Williams Laura A | Chief Patient Officer |
May 21 '26 |
Sale |
6.27 |
6,989 |
43,804 |
429,093 |
| RAAB MICHAEL | President & CEO |
May 21 '26 |
Sale |
6.27 |
54,748 |
343,133 |
1,720,033 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):